Scotiabank Maintains Sector Outperform on BridgeBio Pharma, Raises Price Target to $48

Benzinga · 11/25 23:22
Scotiabank analyst Greg Harrison maintains BridgeBio Pharma (NASDAQ:BBIO) with a Sector Outperform and raises the price target from $45 to $48.